333 related articles for article (PubMed ID: 27993816)
1. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Bell R; Brown J; Parmar M; Toi M; Suter T; Steger GG; Pivot X; Mackey J; Jackisch C; Dent R; Hall P; Xu N; Morales L; Provencher L; Hegg R; Vanlemmens L; Kirsch A; Schneeweiss A; Masuda N; Overkamp F; Cameron D
Ann Oncol; 2017 Apr; 28(4):754-760. PubMed ID: 27993816
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P; Huober J; Untch M; Blohmer JU; Janni W; Denkert C; Klare P; Link T; Rhiem K; Bayer C; Reinisch M; Bjelic-Radisic V; Zahm DM; Hanusch C; Solbach C; Heinrich G; Hartkopf AD; Schneeweiss A; Fasching P; Filmann N; Nekljudova V; Holtschmidt J; Stickeler E; Loibl S
ESMO Open; 2024 May; 9(5):103009. PubMed ID: 38663168
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
6. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Miller KD; O'Neill A; Gradishar W; Hobday TJ; Goldstein LJ; Mayer IA; Bloom S; Brufsky AM; Tevaarwerk AJ; Sparano JA; Le-Lindqwister NA; Hendricks CB; Northfelt DW; Dang CT; Sledge GW
J Clin Oncol; 2018 Sep; 36(25):2621-2629. PubMed ID: 30040523
[TBL] [Abstract][Full Text] [Related]
7. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
Diéras V; Campone M; Yardley DA; Romieu G; Valero V; Isakoff SJ; Koeppen H; Wilson TR; Xiao Y; Shames DS; Mocci S; Chen M; Schmid P
Ann Oncol; 2015 Sep; 26(9):1904-1910. PubMed ID: 26202594
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
[TBL] [Abstract][Full Text] [Related]
10. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
12. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
[TBL] [Abstract][Full Text] [Related]
15. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
[TBL] [Abstract][Full Text] [Related]
17. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
19. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
